Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.79 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9790621 | 0.97 | FDPS (0.79) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7165656 | 0.89 | FDPS (1.00) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9790607 | 0.87 | FDPS (0.96) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9790837 | 0.87 | FDPS (0.67) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9790662 | 0.70 | FDPS (0.80) | FDPSNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL9790768 | 0.70 | FDPS (0.80) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL19468539 | 0.68 | FDPS (0.58) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9790861 | 0.68 | FDPS (0.58) | FDPSNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9790787 | 0.66 | KDR (0.53) | FDPS | |
| SCHEMBL9790750 | 0.66 | FDPS (0.41) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5057505-A | Treatment of illnesses attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |